company background image
BMY logo

Bristol-Myers Squibb NYSE:BMY Stock Report

Last Price

US$60.08

Market Cap

US$121.9b

7D

-0.3%

1Y

16.5%

Updated

20 Mar, 2025

Data

Company Financials +

Bristol-Myers Squibb Company

NYSE:BMY Stock Report

Market Cap: US$121.9b

BMY Stock Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More details

BMY fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends4/6

Rewards

Trading at 58.7% below our estimate of its fair value

Earnings are forecast to grow 31.86% per year

Trading at good value compared to peers and industry

Risk Analysis

Has a high level of debt

Dividend of 4.13% is not well covered by earnings


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

BMY logo
Bristol-Myers Squibb
EV
Evangelos
Community Contributor

Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value

Fourth Quarter 2024 Highlights: Total Revenues: $12.3 billion, an 8% increase from the same period in 2023. GAAP Earnings Per Share (EPS): $0.04, a significant decrease from $0.87 in Q4 2023.
View narrative
US$65.00
FV
7.6% undervalued intrinsic discount
2.43%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
23 days ago author updated this narrative
BMY logo
Bristol-Myers Squibb
AN
Analyst Price Target
Consensus Narrative from 21 Analysts

Relaunch Into Neuroscience With Cobenfy Will Diversify Future Drug Portfolio

Key Takeaways Relaunch into neuroscience with Cobenfy shows potential for revenue through expansion into Alzheimer's and bipolar disorder. Operational and financial strategies focus on cost savings and accelerated R&D to strengthen margins and boost profitability.
View narrative
US$61.24
FV
1.9% undervalued intrinsic discount
-3.91%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
166users have followed this narrative
Updated narrative
View Bristol-Myers Squibb Community

Bristol-Myers Squibb Company Competitors

Zoetis

NYSE:ZTS

US$73.6b

Pfizer

NYSE:PFE

US$149.2b

Merck

NYSE:MRK

US$239.3b

Johnson & Johnson

NYSE:JNJ

US$392.8b

Price History & Performance

Summary of share price highs, lows and changes for Bristol-Myers Squibb
Historical stock prices
Current Share PriceUS$60.08
52 Week HighUS$63.33
52 Week LowUS$39.35
Beta0.44
1 Month Change10.38%
3 Month Change4.80%
1 Year Change16.46%
3 Year Change-17.03%
5 Year Change14.99%
Change since IPO2,711.79%

Recent News & Updates

Bristol-Myers Squibb: Why I'm Still Bullish

Mar 18

Recent updates

Bristol-Myers Squibb: Why I'm Still Bullish

Mar 18

Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success

Feb 21

Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down

Feb 07

Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain

Jan 31

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62

Dec 29
Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62

Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued

Dec 20

Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year

Dec 15
Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year

Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)

Nov 27
Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)

5 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)

Nov 25

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Oct 28

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

Oct 06

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

Sep 27

Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows

Sep 06

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15
Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Aug 06

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Jul 27

Bristol Myers Squibb: The More It Drops, The More I Buy

Jul 16

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Jun 13
Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Jun 09

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

Jun 03

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

May 23

Shareholder Returns

BMYUS PharmaceuticalsUS Market
7D-0.3%1.1%2.1%
1Y16.5%0.6%8.1%

Return vs Industry: BMY exceeded the US Pharmaceuticals industry which returned 0.6% over the past year.

Return vs Market: BMY exceeded the US Market which returned 8.1% over the past year.

Price Volatility

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement3.6%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement6.4%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: BMY has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BMY's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
188734,100Chris Boernerwww.bms.com

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Bristol-Myers Squibb Company Fundamentals Summary

How do Bristol-Myers Squibb's earnings and revenue compare to its market cap?
BMY fundamental statistics
Market capUS$121.92b
Earnings (TTM)-US$8.95b
Revenue (TTM)US$48.30b

2.5x

P/S Ratio

-13.6x

P/E Ratio

Is BMY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BMY income statement (TTM)
RevenueUS$48.30b
Cost of RevenueUS$11.95b
Gross ProfitUS$36.35b
Other ExpensesUS$45.30b
Earnings-US$8.95b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 24, 2025

Earnings per share (EPS)-4.41
Gross Margin75.26%
Net Profit Margin-18.53%
Debt/Equity Ratio303.3%

How did BMY perform over the long term?

See historical performance and comparison

Dividends

4.1%

Current Dividend Yield

-55%

Payout Ratio

Does BMY pay a reliable dividends?

See BMY dividend history and benchmarks
When do you need to buy BMY by to receive an upcoming dividend?
Bristol-Myers Squibb dividend dates
Ex Dividend DateApr 04 2025
Dividend Pay DateMay 01 2025
Days until Ex dividend15 days
Days until Dividend pay date42 days

Does BMY pay a reliable dividends?

See BMY dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/20 07:57
End of Day Share Price 2025/03/19 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bristol-Myers Squibb Company is covered by 44 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Charles ButlerBarclays